Drugs that contain Aprepitant

1. List of Aponvie drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

Market Authorisation Date: 16 September, 2022

Treatment: A method of administering aprepitant for prevention of post-operative nausea and vomiting

Dosage: EMULSION;INTRAVENOUS

More Information on Dosage

APONVIE family patents

14

United States

3

Japan

1

Korea, Republic of

1

China

1

European Union

2. List of Cinvanti drug patents

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US10953018 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974794 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9561229 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10624850 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US11173118 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US9974793 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US10500208 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

US9974742 HERON THERAPS INC Emulsion formulations of an NK-1 receptor antagonist and uses thereof
Sep, 2035

(12 years from now)

US9808465 HERON THERAPS INC Emulsion formulations of aprepitant
Sep, 2035

(12 years from now)

Market Authorisation Date: 09 November, 2017

Treatment: Treatment of nausea and vomiting, including the prevention of acute and delayed nausea and vomiting associated with initial and repeat courses of highly or moderately emetogenic cancer chemotherapy

Dosage: EMULSION;INTRAVENOUS

How can I launch a generic of CINVANTI before it's patent expiration?
More Information on Dosage

CINVANTI family patents

14

United States

3

Japan

1

Korea, Republic of

1

China

1

European Union

3. List of Emend drug patents

EMEND's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MERCK Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(4 years from now)

Market Authorisation Date: 26 March, 2003

Treatment: Prevention of postoperative nausea and vomiting; For the prevention of nausea and vomiting associated with chemotherapy

Dosage: CAPSULE;ORAL

How can I launch a generic of EMEND before it's patent expiration?
More Information on Dosage

EMEND family patents

3

United States

1

ME

YU

1

Yugoslavia

1

Poland

1

Dominican Republic

1

Canada

1

Georgia

1

Slovenia

1

Korea, Republic of

1

Ukraine

1

Brazil

1

Hong Kong

1

Taiwan

1

China

1

Iceland

1

Germany

1

Japan

1

Denmark

1

Croatia

1

Malaysia

1

Hungary

1

Argentina

1

Spain

1

Mexico

1

New Zealand

EA

1

EA

1

Colombia

1

Australia

1

Norway

1

South Africa

1

Ecuador

1

Austria

1

Portugal

1

Israel

1

Jordan

1

Peru

1

European Union

4. List of Emend drug patents

EMEND's oppositions filed in EPO
Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8258132 MSD MERCK CO Pharmaceutical composition of a tachykinin receptor antagonist
Sep, 2027

(4 years from now)

Market Authorisation Date: 17 December, 2015

Treatment: Prevention of nausea and vomiting associated with chemotherapy (cinv)

Dosage: FOR SUSPENSION;ORAL

How can I launch a generic of EMEND before it's patent expiration?
More Information on Dosage

EMEND family patents

3

United States

1

ME

YU

1

Yugoslavia

1

Poland

1

Dominican Republic

1

Canada

1

Georgia

1

Slovenia

1

Korea, Republic of

1

Ukraine

1

Brazil

1

Hong Kong

1

Taiwan

1

China

1

Iceland

1

Germany

1

Japan

1

Denmark

1

Croatia

1

Malaysia

1

Hungary

1

Argentina

1

Spain

1

Mexico

1

New Zealand

EA

1

EA

1

Colombia

1

Australia

1

Norway

1

South Africa

1

Ecuador

1

Austria

1

Portugal

1

Israel

1

Jordan

1

Peru

1

European Union

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic